Lupin partners with Mark Cuban Cost Plus Drug Company, COPD Foundation to expand medication access

Lupin is partnering with Mark Cuban Cost Plus Drug Company and the COPD Foundation, in an effort to bolster access to health care by expanding the availability of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, to COPD patients in the United States.

Lupin’s Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, is currently the only generic product available that is therapeutically equivalent to Boehringer Ingelheim’s Spiriva HandiHaler. 

Chronic obstructive pulmonary disease affects over 15 million adults in the United States and ranks as the fourth leading cause of death in the country. This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the United States, Lupin said.

[Read more: Lupin launches generic HandiHaler, receives FDA OK for 2 generics]

Spiro Gavaris, president of U.S. generics at Lupin said, “We believe there is a large unmet need for improved and affordable products for patients in the United States. As a leading healthcare organization, we are committed to increasing access for patients, seeking treatment options for respiratory conditions like COPD, with our respiratory portfolio and pipeline. Our collaboration with Mark Cuban Cost Plus Drug Company and the COPD Foundation reflects our intent to provide quality treatment options for patients.”

“We are excited to work with Lupin and the COPD Foundation to bring lower prescription drug prices to consumers,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company. “Cost Plus Drugs, Lupin and the COPD Foundation all share a common goal of providing consumers the lowest possible price for their prescription medication. With Cost Plus Drugs, consumers can be confident they are getting a fair price and the convenience of medication mailed directly to their homes.”

[Read more: Mark Cuban Cost Plus Drug Company partners with Coherus to offer Humira biosimilar]

“Accessible and affordable medications are a pathway to a healthier, more empowered life for COPD patients,” said Jean Wright, CEO of the COPD Foundation. “Breathing freely shouldn’t come at the cost of financial strain. Having a generic option will ensure that vital treatments remain within reach, allowing patients to prioritize their health.”